At SKYE Bioscience (OTCMKTS: SKYE) we are focused on the development of novel cannabinoid- based therapies with strong clinical and commercial differentiation for the treatment of glaucoma and other diseases with significant unmet needs.
CEO & Chair
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
During his tenure at OncoSec, he oversaw and completed a partnership with Merck to launch Keynote 695, a Phase 2/3 global multi-center registration clinical study of late-stage metastatic melanoma, raised over $200 million and uplisted the company from the OTCQB to NASDAQ. Since moving on from this role, he has worked in various management capacities and helped to raise $500M for several companies, working together to reach essential milestones.
His experience spans corporate finance, M&A, integration, successful in-licensing of key intellectual property, strategy implementation, international corporate transactions, and collaborations with leading universities and key opinion leaders.
He also serves on the board of directors of other life science companies and acts as an advisor and consultant in several capacities to different life science organizations. He is the creator of Torpedo Publishing, a publishing imprint serving to connect, inspire, and educate future game changers looking to positively impact the world.
Mr. Dhillon is the recipient of the Most Admired CEO award by the San Diego Business Journal in 2017, the BIOCOM Catalyst Award in 2018, the BASS Community Impact Award (SFU Beedie School of Business) in 2018, and has been recognized as a finalist for Ernst & Young’s Annual Entrepreneur of the Year in 2014.